Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial.

J P Lindenmayer; J Volavka; J Lieberman; B Sheitman; L Citrome; M Chakos; P Czobor; B Parker; A Iskander

doi:10.1097/00004714-200108000-00014

Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial.

Identifier:nobleid.org/w1/20260515/D34B92FD

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/D34B92FD.svg?ark=w1%2F20260515%2FD34B92FD)](https://nobleid.org/work/w1/20260515/D34B92FD)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial.

Identifier:nobleid.org/w1/20260515/D34B92FD

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/D34B92FD.svg?ark=w1%2F20260515%2FD34B92FD)](https://nobleid.org/work/w1/20260515/D34B92FD)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work